These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25933675)

  • 1. Next-generation sequencing-based panel testing for myeloid neoplasms.
    Kuo FC; Dong F
    Curr Hematol Malig Rep; 2015 Jun; 10(2):104-11. PubMed ID: 25933675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
    Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
    Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Value of Next-Generation Sequencing in the Screening and Evaluation of Hematologic Neoplasms in Clinical Practice.
    Northrup V; Maybank A; Carson N; Rahmeh T
    Am J Clin Pathol; 2020 Apr; 153(5):639-645. PubMed ID: 31875888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Interpretation of Sequence Variants in Myeloid Neoplasms.
    Hanbazazh M; Harada S; Reddy V; Mackinnon AC; Harbi D; Morlote D
    Am J Clin Pathol; 2021 Oct; 156(5):728-748. PubMed ID: 34155503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.
    Maes B; Willemse J; Broekmans A; Smets R; Cruys B; Put N; Madoe V; Janssen M; Soepenberg O; Bries G; Vrelust I; Achten R; Van Pelt K; Buvé K; Theunissen K; Peeters V; Froyen G
    Int J Lab Hematol; 2017 Dec; 39(6):604-612. PubMed ID: 28722833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.
    Mukherjee S; Sathanoori M; Ma Z; Andreatta M; Lennon PA; Wheeler SR; Prescott JL; Coldren C; Casey T; Rietz H; Fasig K; Woodford R; Hartley T; Spence D; Donnelan W; Berdeja J; Flinn I; Kozyr N; Bouzyk M; Correll M; Ho H; Kravtsov V; Tunnel D; Chandra P
    Cancer Genet; 2017 Oct; 216-217():128-141. PubMed ID: 29025587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic testing in myeloid malignancy.
    Docking TR; Karsan A
    Int J Lab Hematol; 2019 May; 41 Suppl 1():117-125. PubMed ID: 31069982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Pathology: Prognostic and Diagnostic Genomic Markers for Myeloid Neoplasms.
    Kuo FC
    Surg Pathol Clin; 2016 Sep; 9(3):475-88. PubMed ID: 27523973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS.
    Alberti MO; Srivatsan SN; Shao J; McNulty SN; Chang GS; Miller CA; Dunlap JB; Yang F; Press RD; Gao Q; Ding L; Heusel JW; Duncavage EJ; Walter MJ
    Leukemia; 2018 Aug; 32(8):1874-1878. PubMed ID: 29959414
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of an Abnormal Myeloid Clone by Flow Cytometry in Familial Platelet Disorder With Propensity to Myeloid Malignancy.
    Ok CY; Leventaki V; Wang SA; Dinardo C; Medeiros LJ; Konoplev S
    Am J Clin Pathol; 2016 Feb; 145(2):271-6. PubMed ID: 26800764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use.
    Bacher U; Shumilov E; Flach J; Porret N; Joncourt R; Wiedemann G; Fiedler M; Novak U; Amstutz U; Pabst T
    Blood Cancer J; 2018 Nov; 8(11):113. PubMed ID: 30420667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular findings in myeloid neoplasms.
    Tran TB; Siddon AJ
    Int J Lab Hematol; 2023 Aug; 45(4):442-448. PubMed ID: 37345257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory.
    Kanagal-Shamanna R; Singh RR; Routbort MJ; Patel KP; Medeiros LJ; Luthra R
    Expert Rev Mol Diagn; 2016; 16(4):461-72. PubMed ID: 26765348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.
    Rosenthal SH; Gerasimova A; Ma C; Li HR; Grupe A; Chong H; Acab A; Smolgovsky A; Owen R; Elzinga C; Chen R; Sugganth D; Freitas T; Graham J; Champion K; Bhattacharya A; Racke F; Lacbawan F
    PLoS One; 2021; 16(4):e0243683. PubMed ID: 33909614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of amplicon-based next-generation sequencing in cancer.
    Chang F; Li MM
    Cancer Genet; 2013 Dec; 206(12):413-9. PubMed ID: 24332266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance and utility of a comprehensive next-generation sequencing DNA panel for the simultaneous analysis of variants, TMB and MSI for myeloid neoplasms.
    Sahajpal NS; Mondal AK; Ananth S; Njau A; Ahluwalia P; Jones K; Ahluwalia M; Okechukwu N; Savage NM; Kota V; Rojiani AM; Kolhe R
    PLoS One; 2020; 15(10):e0240976. PubMed ID: 33075099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies.
    Levy MA; Santos S; Kerkhof J; Stuart A; Aref-Eshghi E; Guo F; Hedley B; Wong H; Rauh M; Feilotter H; Berardi P; Semenuk L; Yang P; Knoll J; Ainsworth P; McLachlin CM; Chin-Yee I; Kovacs M; Deotare U; Lazo-Langner A; Hsia C; Keeney M; Xenocostas A; Howlett C; Lin H; Sadikovic B
    Eur J Haematol; 2019 Sep; 103(3):178-189. PubMed ID: 31177553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of genome-wide copy number variants in myeloid malignancies using next-generation sequencing.
    Shen W; Paxton CN; Szankasi P; Longhurst M; Schumacher JA; Frizzell KA; Sorrells SM; Clayton AL; Jattani RP; Patel JL; Toydemir R; Kelley TW; Xu X
    J Clin Pathol; 2018 Apr; 71(4):372-378. PubMed ID: 29197855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report.
    Lee TD; Aisner DL; David MP; Eno CC; Gagan J; Gocke CD; Guseva NV; Haley L; Jajosky AN; Jones D; Mansukhani MM; Mroz P; Murray SS; Newsom KJ; Paulson V; Roy S; Rushton C; Segal JP; Senaratne TN; Siddon AJ; Starostik P; Van Ziffle JAG; Wu D; Xian RR; Yohe S; Kim AS
    Blood Adv; 2023 Aug; 7(16):4599-4607. PubMed ID: 37236162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Philadelphia-Negative Myeloproliferative Neoplasms: Laboratory Workup in the Era of Next-Generation Sequencing.
    Zuo Z; Li S; Xu J; You MJ; Khoury JD; Yin CC
    Curr Hematol Malig Rep; 2019 Oct; 14(5):376-385. PubMed ID: 31388824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.